Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05904327
Active, not recruiting Observational

Circulating Biomarkers in Oropharyngeal Cancers

NCT05904327 · tracked via the Priya Life Science Sweden tracker
Sponsor
Region Örebro County
Phase
Observational
Started
2020-12-01
Last updated
2023-06-15

Condition(s) studied

Oropharynx Squamous Cell CarcinomaOropharynx CancerTonsillar CancerBase of the Tongue Carcinoma

Study summary

The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck. The main questions it aims to answer are:

* Can ctHPV-DNA be used for treatment evaluation in HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck?
* Can circulating HPV-DNA be used as a biomarker for recurrent disease during surveillance?

Participants will be asked to leave plasma samples at diagnose, at the end of treatment and at every clinical follow-up.

The patients are there own controls.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Oropharyngeal cancer * Cancer of unknown primary in the head and neck Exclusion Criteria: * Previous treatment of cancer in the oropharynx. * Previous treatment of unknown primary tumor. * Remote metastases * Patients unwilling or unable to comply with the study protocol and follow-up schedule

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Anna Oldaeus Almerén Örebro Sweden

More Region Örebro County trials in Sweden

Reablement in Residential Aged Care - a Randomized Controlled Trail Recruiting
Internet Treatment for Patients With Obesity Active, not recruiting
Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE Recruiting
Digitally Distributed Yoga for Women Treated for Breast Cancer Active, not recruiting
Functional Vision and Quality of Life in a Modern Society - With Emphasis on Myopia and Cerebral Visual Impairment Among Youth Recruiting

Other trials for the same condition

Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05904327 on ClinicalTrials.gov ↗ ← All trials in Sweden